Clinical Study on Treatment of Migraine with AnXian-lamotrigine (LTG): an open-label controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TCC-09000551

Enrollment

Unknown

Registered

2009-09-16

Start date

2009-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

migraine

Interventions

Group A:Lamotrigine

Group B:Lamotrigine together with Flunarizine

Group C:Other Anti-Epilepsy Drugs (AEDs) transferred to Lamotrigine

Group D:Other Anti-Epilepsy Drugs (AEDs) transferred to Lamotrigine together with Flunarizine

Eligibility

Sex/Gender

All

Age

15 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Male and female patients aged 15 to 75 years old who were concordant for migraine of International Headache Society (2003); 2. Admitted in Nanjing Brain Hospital between Jan 1st 2009 and Dec 31 2010; 3. Diagnosed by experienced physicians; 4. signed the consent form.

Exclusion criteria

Exclusion criteria: 1. Been involved in a similar clinical trial in the past four weeks; 2. With severe systemic disorders; 3. Allergic to Lamotrigine; 4. Drug and/or alcohol abuse; 5. Pregnant and lactant women; 6. Refuse to sign the consent form.

Design outcomes

Primary

Measure	Time frame
Change in the Number of Migraine Days;MIGSEV scale;Frequency of Migraine;	—

Secondary

Measure	Time frame
quality of life;	—

Countries

China

Contacts

Public ContactJun Xu

neurojun@126.com+86 13951840403

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026